AI Article Synopsis

  • Deep Brain Stimulation (DBS) and Motor Cortex Stimulation (MCS) are invasive therapies used to treat neuropathic pain like Central Post-Stroke Pain, but there's been no thorough comparison of their effectiveness using standardized pain metrics.
  • A systematic review and meta-analysis were conducted, reviewing 32 studies (330 patients) and measuring pain relief through VAS and NRS scores, finding that MCS had a slightly better improvement rate compared to DBS.
  • Despite showing MCS as potentially more effective, further studies are needed to establish the best surgical approach for treating Central Post-Stroke Pain.

Article Abstract

Introduction: Deep Brain Stimulation (DBS) and Motor Cortex stimulation (MCS) are invasive interventions in order to treat various neuropathic pain syndromes such as Central Post-Stroke Pain. While each treatment has varying degree of success, comparative analysis has not yet been performed, and the success rates of these techniques using validated, objective pain scores have not been synthesised.

Methods: A systematic review and meta-analysis was conducted in accordance with PRISMA guidelines. Three databases were searched, and articles published from January 2000 October 2024 were included (last search date 25 October 2024). Meta-Analysis was performed using random effects models. We evaluated the performance of DBS or MCS by assessing studies that reported pain relief using Visual Analogue Scale (VAS) or Numerical Rating Scale (NRS) scores.

Results: Of the 478 articles identified, 32 were included in the analysis (330 patients- 139 DBS, & 191 MCS). The improvement in mean VAS score for patients that underwent DBS post-surgery was 48.6% compared to a score of 53.1% for patients that had MCS. The pooled number of patients who improved after DBS was 0.62 (95% CI, 0.51-0.71, I2=16%). The pooled number of patients who improved after MCS was 0.64 (95% CI, 0.53-0.74, I2=40%).

Conclusion: The use of neurosurgical interventions such as DBS and MCS are last-resort treatments for Central Post-Stroke Pain, with limited studies exploring and comparing these two techniques. While our study shows that MCS might be a slightly better treatment option, further research would need to be done to determine the appropriate surgical intervention in the treatment of Central Post-Stroke Pain.

Download full-text PDF

Source
http://dx.doi.org/10.1093/pm/pnaf001DOI Listing

Publication Analysis

Top Keywords

central post-stroke
16
post-stroke pain
16
deep brain
8
brain stimulation
8
stimulation dbs
8
dbs motor
8
motor cortex
8
cortex stimulation
8
mcs
8
stimulation mcs
8

Similar Publications

Article Synopsis
  • Deep Brain Stimulation (DBS) and Motor Cortex Stimulation (MCS) are invasive therapies used to treat neuropathic pain like Central Post-Stroke Pain, but there's been no thorough comparison of their effectiveness using standardized pain metrics.
  • A systematic review and meta-analysis were conducted, reviewing 32 studies (330 patients) and measuring pain relief through VAS and NRS scores, finding that MCS had a slightly better improvement rate compared to DBS.
  • Despite showing MCS as potentially more effective, further studies are needed to establish the best surgical approach for treating Central Post-Stroke Pain.
View Article and Find Full Text PDF

Background: Timely rehabilitative care is vital for functional recovery after stroke. Social determinants may influence access to and use of post-stroke care but have been inadequately explored. The study examined the relationship between the Social Vulnerability Index (SVI) and community-based rehabilitation utilization.

View Article and Find Full Text PDF

AENK ameliorates cognitive impairment and prevents Tau hyperphosphorylation through inhibiting AEP-mediated cleavage of SET in rats with ischemic stroke.

J Neurochem

January 2025

Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education Ministry/Hubei Province of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Brain damage induced by ischemia promotes the development of cognitive dysfunction, thus increasing the risk of dementia such as Alzheimer's disease (AD). Studies indicate that cellular acidification-triggered activation of asparagine endopeptidase (AEP) plays a key role in ischemic brain injury, through multiple molecular pathways, including cleavage of its substrates such as SET (inhibitor 2 of PP2A, I ) and Tau. However, whether direct targeting AEP can effectively prevent post-stroke cognitive impairment (PSCI) remains unanswered.

View Article and Find Full Text PDF

Background: Stroke is one of the most serious illnesses worldwide and is the primary cause of acquired disability among adults. Post-stroke cognitive impairment (PSCI) is a complication of stroke that significantly impacts patients' daily activities and social functions. Therefore, developing a risk prediction model for PSCI is essential for identifying and preventing disease progression.

View Article and Find Full Text PDF

Introduction: The progression of diabetes status in post-stroke patients remains under-investigated, particularly regarding new treatments for type II diabetes mellitus (DM II), like glucagon-like peptide 1 receptor agonists (GLP-1-RA) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors, which have not been studied in the post-stroke setting.

Patients And Methods: Eight hundred eighty-four consecutive ischemic stroke patients recruited to our prospective STROKE-CARD Registry were assessed concerning their glycemic status at baseline (normoglycemia, prediabetes, DM II) and change over time within 1 year follow-up. Multivariate logistic regression was performed to identify factors associated with transitioning from normoglycemia to prediabetes or DM II.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!